Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia

Launched by EMS · Oct 14, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a product called Finlândia hair lotion for treating a common type of hair loss known as androgenetic alopecia, which affects many men. The trial is currently looking for male participants aged between 18 and 60 years who have been diagnosed with specific grades of hair loss and have been using a different hair loss treatment (minoxidil 5%) for at least three months. Participants should be willing to keep their hair style, length, and color consistent throughout the study.

If you decide to participate, you'll be asked to sign an informed consent form, confirming that you understand the trial and want to take part. Some individuals may not be eligible due to factors like allergies to the treatment ingredients, certain medical conditions, or recent use of other hair loss treatments. Throughout the trial, you can expect regular check-ins and assessments to monitor your progress and the effects of the lotion. This study aims to find out if the new lotion can help improve hair growth and is an important step in understanding better treatment options for hair loss.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms;
• • Men aged 18 years or over and less than or equal to 60 years with a diagnosis of Androgenetic Alopecia grades IIIv to IV in the modified Norwood-Hamilton classification, who have been using minoxidil 5% for at least 3 months and willing to maintain the same style, approximate length and hair color throughout the test.
• Exclusion Criteria:
• • Known hypersensitivity to the formula components used during the clinical trial;
• • History of alcohol and/or substance abuse within 2 years;
• • Participants with other concomitant dermatological diseases on the scalp, except for mild seborrhoea dermatitis;
• • Participants with a history of surgical treatment for hair loss or shaved scalp;
• • Participants who used shampoo or topical solution containing ketoconazole, tar, selenium, threonine or steroids in the last 2 weeks;
• • Participants who used 5α reductase inhibitors, such as finasteride and dutasteride, in the last 12 months;
• • Participants using testosterone replacement therapy (TRT) or using testosterone-containing gel;
• • Participants who used micro-infusion of medications on the skin (MMP), microneedling or intradermotherapy on the scalp in the last 3 months;
• • Participants who have undergone radiation treatment for the scalp or chemotherapy in the past year;
• • Participants with diseases that can affect hair growth;
• • Participants with a current medical history of cancer and / or cancer treatment in the last 5 years;